AnaptysBio (ANAB) Expected to Announce Earnings on Tuesday

Key Points

• AnaptysBio is expected to report Q3 2026 results after market close on Tuesday, November 3. Analysts forecast a loss of $1.84 per share and revenue of $25.56 million, with the conference call scheduled for November 4.
• The company’s previous quarter significantly exceeded expectations, reporting $5.11 in EPS versus a $0.46 loss estimate and $27.49 million in revenue versus the $14.06 million consensus.
• Analysts maintain a “Moderate Buy” consensus with an average $77.79 price target, although some firms recently downgraded the stock or reduced targets. Shares opened at $48.77, well below the consensus target.

AnaptysBio (NASDAQ:ANAB - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect AnaptysBio to announce earnings of ($1.84) per share and revenue of $25.56 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $5.57. The business had revenue of $27.49 million during the quarter, compared to analysts' expectations of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%. During the same quarter last year, the business posted ($1.30) EPS. On average, analysts expect AnaptysBio to post ($1.30) EPS for the current fiscal year and $2.42 EPS for the next fiscal year.

AnaptysBio Price Performance

Shares of ANAB opened at $48.77 on Tuesday. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of 9.08 and a beta of 0.76. AnaptysBio has a 1 year low of $20.18 and a 1 year high of $72.36. The business's 50 day simple moving average is $52.70 and its 200-day simple moving average is $56.21.

Insiders Place Their Bets

In related news, Director Hollings Renton sold 5,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the sale, the director owned 10,995 shares in the company, valued at approximately $548,320.65. This represents a 31.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 31.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ANAB shares. Scotiabank cut shares of AnaptysBio to a "hold" rating and set a $70.00 price target on the stock. in a research report on Tuesday, August 25th. Leerink Partners lowered their price objective on shares of AnaptysBio from $90.00 to $81.00 and set an "outperform" rating for the company in a research report on Wednesday, September 23rd. Wall Street Zen lowered shares of AnaptysBio from a "buy" rating to a "hold" rating in a research report on Sunday, October 4th. TD Cowen dropped their price objective on shares of AnaptysBio from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, August 25th. Finally, Wolfe Research restated an "outperform" rating and issued a $78.00 target price on shares of AnaptysBio in a report on Monday, August 31st. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AnaptysBio currently has an average rating of "Moderate Buy" and an average target price of $77.79.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio's pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.